Literature DB >> 33674939

Treatment burden in multiple myeloma according to comorbidity in real life.

Ernesto Pérez Persona1, Itziar Oiartzabal Ormategui2, Laida Cuevas Palomares3, Ana Santamaría López4, Diego Robles de Castro3, Carlos Miguel de Sánchez3, Miren Gabilondo Jalón3, Carlos Pisón Herrero3, Ariane Unamunzaga Cilaurren3, Ana Vega González de Viñaspre3, Jose María Guinea de Castro3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33674939     DOI： 10.1007/s00277-021-04462-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  12 in total

1.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

2.  Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.

Authors:  Luciano J Costa; Parameswaran N Hari; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2016-04-22

3.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

4.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.

Authors:  Tobias W Klausen; Henrik Gregersen; Niels Abildgaard; Niels Frost Andersen; Ulf Christian Frølund; Peter Gimsing; Carsten Helleberg; Annette J Vangsted
Journal:  Leukemia       Date:  2018-09-28       Impact factor: 11.528

6.  Multiple myeloma: patient outcomes in real-world practice.

Authors:  Kwee Yong; Michel Delforge; Christoph Driessen; Leah Fink; Alain Flinois; Sebastian Gonzalez-McQuire; Reza Safaei; Lionel Karlin; Maria-Victoria Mateos; Marc S Raab; Paul Schoen; Michele Cavo
Journal:  Br J Haematol       Date:  2016-07-13       Impact factor: 6.998

7.  A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Authors:  Thierry Facon; Meletios A Dimopoulos; Nathalie Meuleman; Andrew Belch; Mohamad Mohty; Wen-Ming Chen; Kihyun Kim; Elena Zamagni; Paula Rodriguez-Otero; William Renwick; Christian Rose; Adrian Tempescul; Eileen Boyle; Salomon Manier; Michel Attal; Philippe Moreau; Margaret Macro; Xavier Leleu; Marie Lorraine Chretien; Heinz Ludwig; Shien Guo; Michael Sturniolo; Antoine Tinel; Mara Silvia Monzini; Bruno Costa; Vanessa Houck; Cyrille Hulin; Jean Yves Mary
Journal:  Leukemia       Date:  2019-08-19       Impact factor: 11.528

Review 8.  Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Authors:  Paul G Richardson; Jesus F San Miguel; Philippe Moreau; Roman Hajek; Meletios A Dimopoulos; Jacob P Laubach; Antonio Palumbo; Katarina Luptakova; Dorothy Romanus; Tomas Skacel; Shaji K Kumar; Kenneth C Anderson
Journal:  Blood Cancer J       Date:  2018-11-09       Impact factor: 11.037

9.  Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms.

Authors:  Wolfgang Knauf; Ali Aldaoud; Ulrich Hutzschenreuter; Martine Klausmann; Stephanie Dille; Natalie Wetzel; Martina Jänicke; Norbert Marschner
Journal:  Ann Hematol       Date:  2018-08-01       Impact factor: 3.673

Review 10.  Multiple myeloma current treatment algorithms.

Authors:  S Vincent Rajkumar; Shaji Kumar
Journal:  Blood Cancer J       Date:  2020-09-28       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.